OneSource Specialty Pharma
OneSource Specialty Pharma Ltd valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for OneSource Specialty Pharma Ltd, framed against the sector median so the premium or discount is obvious at a glance.
Valuation
Profitability
Growth
Financial Health
OneSource Specialty Pharma Ltd financials: P&L, balance sheet, cash flow, ratios.
Twelve years of audited numbers for OneSource Specialty Pharma Ltd, switchable between annual and quarterly views, consolidated or standalone.
OneSource Specialty Pharma Ltd reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹18,397.85 Cr and reported EPS of ₹-6.44.
| Period | 2025 | 2026 |
|---|---|---|
| Revenue from Operations | 1,445 | 1,422 |
| Other Income | 17 | 15 |
| Total Income | 1,462 | 1,437 |
| Cost of Goods Sold (COGS) | 435 | 445 |
| Gross Profit | 1,010 | 977 |
| +Operating Expenses | 543 | 673 |
| EBITDA | 467 | 304 |
| +Non-Operating Expenses | 329 | 391 |
| Profit Before Tax (PBT) | -67 | -92 |
| +Tax Expense | -50 | -18 |
| Profit After Tax (PAT) | -17 | -74 |
| Earnings Per Share (EPS) | -1.57 | -6.44 |
| Diluted Shares Outstanding (Nos.) | 11 | 11 |
| +Additional Disclosures | 1,850 | 1,979 |
| Sales Growth % | — | -1.61 |
| YoY Sales Growth % | — | -1.61 |
| Material Cost % | 23 | 31 |
| Employee Cost % | 15 | 17 |
| Other Cost % | 23 | 30 |
| OPM % | 32 | 21 |
| Tax % | 74 | 20 |
| Profit Growth % | — | -327.08 |
| Gross Margin % | 0.00 | 0.00 |
| EBITDA Margin % | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 |
| Additional Fields | 193 | 25 |
OneSource Specialty Pharma segment analysis: revenue and profit mix.
Disclosed business segments at OneSource Specialty Pharma with their share of revenue and profit, switchable between consolidated and standalone reporting.
OneSource Specialty Pharma discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
OneSource Specialty Pharma Ltd investment thesis: bull case, bear case, and the flip lines.
Why someone would buy OneSource Specialty Pharma Ltd, why someone wouldn't, and the quantitative tripwires that would force the call to flip.
OneSource Specialty Pharma Ltd's investment case rests on 7 positive markers and 8 flagged concerns drawn from the latest reported filings.
What you're getting.
The company reported a 12.00% quarter-on-quarter sales growth, indicating a positive trend in revenue generation. This is competitive with peers like Divi's Lab (13.79%) and Mankind Pharma (24.50%).
With a debt-to-equity ratio of 0.13, OneSource maintains a very healthy balance sheet, suggesting low financial risk and strong solvency compared to industry averages.
The company boasts a robust Operating Profit Margin (OPM) of 33.10%, demonstrating efficient cost management and strong operational profitability before interest and taxes.
FII and DII holdings have steadily increased to 19.39% and 18.48% respectively by 2025-09, indicating growing institutional investor confidence in the company's prospects.
As a player in the Pharmaceuticals industry, OneSource can capitalize on the overall sector expansion driven by increasing healthcare demand, R&D advancements, and global market access.
What can break it.
OneSource's P/E ratio of 240.00 is significantly higher than its peers (e.g., Sun Pharma 35.90, Cipla 23.66), suggesting the stock is overvalued relative to its current earnings.
Despite a 268.00% quarterly profit variance, the latest net profit for 2025-06 was negative at -0.19 Cr, highlighting inconsistent and often unprofitable operations.
The company's ROE of 3.34% and ROCE of 5.52% are considerably lower than industry peers (e.g., Divi's Lab ROCE 20.44%), indicating inefficient capital utilization.
Promoter holding has decreased from 37.76% in 2024-12 to 29.77% in 2025-09, which could signal a lack of long-term confidence from the core management.
The stock has shown recent volatility, trading between a 52-week high of 2250.00 and a low of 1163.00, with recent daily changes indicating price fluctuations.
What would change my mind.
Reassess if quarterly profit growth prints below 0% for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 26.29. Balance sheet risk re-prices growth multiples fast.
OneSource Specialty Pharma Ltd peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — OneSource Specialty Pharma Ltd is highlighted for quick read-across.
Quick Compare
Peer Comparison
OneSource Specialty Pharma Ltd technical analysis: indicators, pivots and CPR.
Live RSI, MACD and moving-average signals plus today's pivot and Central Pivot Range levels for OneSource Specialty Pharma Ltd — derived from the live tape, not yesterday's close.
OneSource Specialty Pharma Ltd last traded at ₹1,612.5 with an intraday range of ₹1,591.8–₹1,670 — live indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Live: ₹1612.50| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1814.13 | +201.63 | +12.50% |
| R3 | 1735.93 | +123.43 | +7.65% |
| R2 | 1702.97 | +90.47 | +5.61% |
| R1 | 1657.73 | +45.23 | +2.81% |
| PIVOT | 1624.77 | 12.27 | 0.76% |
| CURRENT | 1612.50 | — | — |
| S1 | 1423.13 | -189.37 | -11.74% |
| S2 | 1501.33 | -111.17 | -6.89% |
| S3 | 1546.57 | -65.93 | -4.09% |
| S4 | 1579.53 | -32.97 | -2.04% |
ONESOURCE is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: 1645.7 ~ 1670
Trading Below opening range, showing Bearishness
OneSource Specialty Pharma Ltd delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for OneSource Specialty Pharma Ltd over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in OneSource Specialty Pharma Ltd stood at 52.9% of traded volume, against a 20-day average of 47.3%.
OneSource Specialty Pharma announcements: results, concalls, ratings, M&A.
Filings OneSource Specialty Pharma sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
OneSource Specialty Pharma files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 132 documents below.
Updates
In furtherance to the clarification sought by the exchange with regard to the OCR readable format of the financial results, Onesource Specialty…
Updates
In furtherance to the intimation made on May 13, 2026, w.r.t the resignation of the SMP, Onesource Specialty Pharma Limited has informed the Exchange…
Updates
Onesource Specialty Pharma Limited has informed the Exchange regarding the receipt of in-principle approval from the Government of Karnataka for the…
Press Release
Onesource Specialty Pharma Limited has informed the Exchange regarding a press release dated May 13, 2026, titled "OneSource Announces FY26 Results…
Investor Presentation
Onesource Specialty Pharma Limited has informed the Exchange about Investor Presentation
Investor decks & rating reports.
OneSource Specialty Pharma insider trading: promoter and management activity.
Promoter, director and designated-employee transactions in OneSource Specialty Pharma as reported to SEBI — buying and selling signals from the people who know the business best.
OneSource Specialty Pharma insider activity below tracks 10 reported promoter, director and designated-employee transactions under SEBI Regulation 7(2).
| Insider | Category | Txn Date | Action | Quantity | Value (₹) | Price |
|---|---|---|---|---|---|---|
| Pronomz Ventures LLP | Insider | 13 Jun 2025 | sell | −51.03 L | ₹1,008.77 Cr | ₹1,977.00 |
| Sajitha Pillai | Insider | 06 Feb 2025 | sell | −5.0 K | ₹77.39 L | ₹1,547.84 |
| Sajitha Pillai | Insider | 05 Feb 2025 | sell | −7.5 K | ₹1.15 Cr | ₹1,532.06 |
| Hemalatha Pillai | Insider | 03 Feb 2025 | sell | −18.0 K | ₹2.62 Cr | ₹1,453.07 |
| Neeraj Sharma | Insider | 03 Feb 2025 | sell | −20.0 K | ₹2.97 Cr | ₹1,487.15 |
| Vineetha Mohankumar Pillai | Insider | 31 Jan 2025 | sell | −47.5 K | ₹7.44 Cr | ₹1,565.38 |
| Padmakumar Karunakaran Pillai | Insider | 31 Jan 2025 | sell | −50.0 K | ₹7.79 Cr | ₹1,558.73 |
| Hemalatha Pillai | Insider | 31 Jan 2025 | sell | −12.0 K | ₹1.9 Cr | ₹1,579.62 |
| Tenshi Pharmaceuticals Private Limited | Insider | 31 Jan 2025 | sell | −33.01 L | ₹505.62 Cr | ₹1,531.74 |
| Pronomz Ventures LLP | Insider | 31 Jan 2025 | sell | −5.83 L | ₹90 Cr | ₹1,545.00 |
OneSource Specialty Pharma dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue OneSource Specialty Pharma has declared, sequenced by announce and record date.
OneSource Specialty Pharma corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About OneSource Specialty Pharma Ltd: business, sector, key facts.
What OneSource Specialty Pharma Ltd does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
OneSource Specialty Pharma Ltd operates in the Healthcare, listed as NSE: ONESOURCE, BSE: 544292.
ONESOURCE Specialty Pharma Limited is a biopharmaceutical company headquartered in Bengaluru, India, focusing on the research, development, manufacturing, and commercialization of biological drug products. Their primary market is both within India and internationally. The company's core business revolves around providing high-quality biologics in various injectable formats, catering to a broad spectrum of pharmaceutical needs.
A significant aspect of ONESOURCE's operations is its comprehensive contract development and manufacturing organization (CDMO) services. These services span the entire lifecycle of drug development, from the preclinical and clinical phases all the way through to the commercial supply of biologics. This end-to-end approach offers clients a streamlined and integrated solution for bringing their biopharmaceutical products to market.
Beyond its CDMO capabilities, ONESOURCE also boasts a robust manufacturing portfolio. This includes the production of a diverse range of drug delivery devices, such as prefilled syringes, various types of pen injectors, and autoinjectors. In addition to these drug-device combinations, they manufacture sterile injectables, soft gelatin capsules, and a variety of biologics solutions. Their manufacturing expertise extends to diverse biopharmaceutical modalities such as microbial and mammalian cell line biopharmaceuticals, cell and gene therapy products, and RNA-based therapeutics.
ONESOURCE's wide-ranging capabilities and integrated approach position it as a significant player in the global biopharmaceutical landscape. The company's commitment to quality and its broad service offering enable it to support the development and supply of a wide variety of biologics, contributing to advancements in healthcare both domestically and internationally. Its recent name change from Stelis Biopharma Limited to ONESOURCE Specialty Pharma Limited reflects a strategic shift towards highlighting its comprehensive and integrated service offering to clients.
Questions investors ask about OneSource Specialty Pharma Ltd (ONESOURCE).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of OneSource Specialty Pharma Ltd (ONESOURCE)?
The current share price of OneSource Specialty Pharma Ltd (ONESOURCE) is ₹1,612.5. Today, the stock has declined by ₹38.90 (2.36%), trading in a range of ₹1,591.8 to ₹1,670. The stock opened at ₹1,655.1 with a trading volume of 3,62,871 shares.
02Is OneSource Specialty Pharma Ltd stock a good investment for long-term?
OneSource Specialty Pharma Ltd can be considered for long-term investment based on several factors. The company has a market capitalization of ₹18,397.85 crores, P/E ratio of 0.00, ROE of -1.26%, and ROCE of 5.52%. The dividend yield stands at 0.00%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of OneSource Specialty Pharma Ltd stock?
The 52-week high price of OneSource Specialty Pharma Ltd (ONESOURCE) is ₹0, while the 52-week low is ₹0. Currently trading at ₹1,612.5, the stock is Infinity% away from its 52-week low and -Infinity% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy OneSource Specialty Pharma Ltd stock at the current price?
Whether to buy OneSource Specialty Pharma Ltd stock at ₹1,612.5 depends on multiple factors. The stock is currently trading with a P/E ratio of 0.00 and P/B ratio of 3.18. Today's performance shows a loss of 2.36%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of OneSource Specialty Pharma Ltd and when is the next dividend?
OneSource Specialty Pharma Ltd offers a dividend yield of 0.00%, which means for every ₹100 invested at the current price of ₹1,612.5, you can expect to receive approximately ₹0.00 annually as dividends. The face value of the stock is ₹1.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of OneSource Specialty Pharma Ltd?
OneSource Specialty Pharma Ltd's key financial metrics include: P/E Ratio: 0.00, P/B Ratio: 3.18, ROE: -1.26%, ROCE: 5.52%, Dividend Yield: 0.00%, EPS: ₹-6.44, Book Value: ₹507.4, and Debt-to-Equity: 25.79. The company's market cap stands at ₹18,397.85 crores. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is OneSource Specialty Pharma Ltd stock performing today in the market?
OneSource Specialty Pharma Ltd stock opened at ₹1,655.1 and is currently trading at ₹1,612.5, showing a decline of ₹38.90 (2.36%). The intraday high is ₹1,670 and low is ₹1,591.8. The trading volume stands at 3,62,871 shares, indicating moderate market participation today.
08What is the P/E ratio of OneSource Specialty Pharma Ltd and what does it indicate?
OneSource Specialty Pharma Ltd has a Price-to-Earnings (P/E) ratio of 0.00, which means investors are willing to pay ₹0.00 for every ₹1 of earnings. With an EPS of ₹-6.44, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about OneSource Specialty Pharma Ltd (ONESOURCE) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- Aarey Drugs & Pharmaceuticals (AAREYDRUGS) Share PricePeer
- Aarti Drugs (AARTIDRUGS) Share PricePeer
- Aarti Pharmalabs (AARTIPHARM) Share PricePeer
- Ajanta Pharma (AJANTPHARM) Share PricePeer
- Akums Drugs & Pharmaceuticals (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy